NYSEAMERICAN:STXS

Stereotaxis Competitors

$7.68
-0.47 (-5.77 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.63
Now: $7.68
$8.22
50-Day Range
$4.42
MA: $5.02
$5.30
52-Week Range
$3.03
Now: $7.68
$8.62
Volume502,499 shs
Average Volume380,843 shs
Market Capitalization$568.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56

Competitors

Stereotaxis (NYSEAMERICAN:STXS) Vs. BLFS, NTUS, AXGN, SMLR, TMDX, and VRAY

Should you be buying STXS stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Stereotaxis, including BioLife Solutions (BLFS), Natus Medical (NTUS), AxoGen (AXGN), Semler Scientific (SMLR), TransMedics Group (TMDX), and ViewRay (VRAY).

BioLife Solutions (NASDAQ:BLFS) and Stereotaxis (NYSEAMERICAN:STXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares BioLife Solutions and Stereotaxis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million38.45$-1,660,000.00$0.08393.88
Stereotaxis$28.90 million19.69$-4,590,000.00($0.10)-76.80

BioLife Solutions has higher earnings, but lower revenue than Stereotaxis. Stereotaxis is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.7% of BioLife Solutions shares are held by institutional investors. Comparatively, 54.3% of Stereotaxis shares are held by institutional investors. 22.3% of BioLife Solutions shares are held by insiders. Comparatively, 34.9% of Stereotaxis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

BioLife Solutions has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Profitability

This table compares BioLife Solutions and Stereotaxis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
Stereotaxis-24.54%-22.78%-13.15%

Analyst Recommendations

This is a summary of current ratings for BioLife Solutions and Stereotaxis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions01902.90
Stereotaxis00203.00

BioLife Solutions currently has a consensus target price of $46.6667, suggesting a potential upside of 48.10%. Stereotaxis has a consensus target price of $8.00, suggesting a potential upside of 4.17%. Given BioLife Solutions' higher probable upside, research analysts clearly believe BioLife Solutions is more favorable than Stereotaxis.

Summary

BioLife Solutions beats Stereotaxis on 10 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Stereotaxis (NYSEAMERICAN:STXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares Natus Medical and Stereotaxis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$495.52 million1.84$-15,670,000.00$1.2421.76
Stereotaxis$28.90 million19.69$-4,590,000.00($0.10)-76.80

Stereotaxis has lower revenue, but higher earnings than Natus Medical. Stereotaxis is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

89.7% of Natus Medical shares are held by institutional investors. Comparatively, 54.3% of Stereotaxis shares are held by institutional investors. 1.5% of Natus Medical shares are held by insiders. Comparatively, 34.9% of Stereotaxis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Natus Medical has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Profitability

This table compares Natus Medical and Stereotaxis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natus Medical-4.33%3.87%2.50%
Stereotaxis-24.54%-22.78%-13.15%

Analyst Recommendations

This is a summary of current ratings for Natus Medical and Stereotaxis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natus Medical01002.00
Stereotaxis00203.00

Stereotaxis has a consensus target price of $8.00, suggesting a potential upside of 4.17%. Given Stereotaxis' stronger consensus rating and higher probable upside, analysts clearly believe Stereotaxis is more favorable than Natus Medical.

AxoGen (NASDAQ:AXGN) and Stereotaxis (NYSEAMERICAN:STXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings for AxoGen and Stereotaxis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
Stereotaxis00203.00

AxoGen currently has a consensus target price of $23.75, suggesting a potential upside of 29.92%. Stereotaxis has a consensus target price of $8.00, suggesting a potential upside of 4.17%. Given AxoGen's higher probable upside, research analysts clearly believe AxoGen is more favorable than Stereotaxis.

Valuation & Earnings

This table compares AxoGen and Stereotaxis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million6.98$-29,140,000.00($0.68)-26.88
Stereotaxis$28.90 million19.69$-4,590,000.00($0.10)-76.80

Stereotaxis has lower revenue, but higher earnings than AxoGen. Stereotaxis is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AxoGen has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Insider and Institutional Ownership

78.4% of AxoGen shares are held by institutional investors. Comparatively, 54.3% of Stereotaxis shares are held by institutional investors. 6.9% of AxoGen shares are held by insiders. Comparatively, 34.9% of Stereotaxis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares AxoGen and Stereotaxis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
Stereotaxis-24.54%-22.78%-13.15%

Stereotaxis (NYSEAMERICAN:STXS) and Semler Scientific (OTCMKTS:SMLR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Stereotaxis and Semler Scientific, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stereotaxis00203.00
Semler Scientific00203.00

Stereotaxis currently has a consensus target price of $8.00, suggesting a potential upside of 4.17%. Semler Scientific has a consensus target price of $110.50, suggesting a potential upside of 3.39%. Given Stereotaxis' higher probable upside, equities analysts plainly believe Stereotaxis is more favorable than Semler Scientific.

Valuation and Earnings

This table compares Stereotaxis and Semler Scientific's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stereotaxis$28.90 million19.69$-4,590,000.00($0.10)-76.80
Semler Scientific$32.77 million21.91$15.08 million$1.8856.85

Semler Scientific has higher revenue and earnings than Stereotaxis. Stereotaxis is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Stereotaxis has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Insider & Institutional Ownership

54.3% of Stereotaxis shares are held by institutional investors. Comparatively, 12.1% of Semler Scientific shares are held by institutional investors. 34.9% of Stereotaxis shares are held by insiders. Comparatively, 13.6% of Semler Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Stereotaxis and Semler Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stereotaxis-24.54%-22.78%-13.15%
Semler Scientific32.08%67.38%52.42%

Summary

Semler Scientific beats Stereotaxis on 8 of the 12 factors compared between the two stocks.

Stereotaxis (NYSEAMERICAN:STXS) and TransMedics Group (NASDAQ:TMDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Stereotaxis and TransMedics Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stereotaxis00203.00
TransMedics Group02302.60

Stereotaxis currently has a consensus target price of $8.00, suggesting a potential upside of 4.17%. TransMedics Group has a consensus target price of $44.20, suggesting a potential upside of 76.52%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Stereotaxis.

Valuation and Earnings

This table compares Stereotaxis and TransMedics Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stereotaxis$28.90 million19.69$-4,590,000.00($0.10)-76.80
TransMedics Group$23.60 million29.04$-33,550,000.00($2.36)-10.61

Stereotaxis has higher revenue and earnings than TransMedics Group. Stereotaxis is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Stereotaxis has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.

Insider & Institutional Ownership

54.3% of Stereotaxis shares are held by institutional investors. Comparatively, 76.7% of TransMedics Group shares are held by institutional investors. 34.9% of Stereotaxis shares are held by insiders. Comparatively, 13.1% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Stereotaxis and TransMedics Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stereotaxis-24.54%-22.78%-13.15%
TransMedics Group-131.35%-38.95%-24.10%

Summary

Stereotaxis beats TransMedics Group on 8 of the 14 factors compared between the two stocks.

Stereotaxis (NYSEAMERICAN:STXS) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Stereotaxis and ViewRay, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stereotaxis00203.00
ViewRay11502.57

Stereotaxis currently has a consensus target price of $8.00, suggesting a potential upside of 4.17%. ViewRay has a consensus target price of $4.50, suggesting a potential upside of 14.21%. Given ViewRay's higher probable upside, analysts plainly believe ViewRay is more favorable than Stereotaxis.

Valuation and Earnings

This table compares Stereotaxis and ViewRay's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stereotaxis$28.90 million19.69$-4,590,000.00($0.10)-76.80
ViewRay$87.78 million7.22$-120,200,000.00($1.18)-3.34

Stereotaxis has higher earnings, but lower revenue than ViewRay. Stereotaxis is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Stereotaxis has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Insider & Institutional Ownership

54.3% of Stereotaxis shares are held by institutional investors. Comparatively, 83.0% of ViewRay shares are held by institutional investors. 34.9% of Stereotaxis shares are held by insiders. Comparatively, 15.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Stereotaxis and ViewRay's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stereotaxis-24.54%-22.78%-13.15%
ViewRay-166.74%-63.41%-36.34%

Summary

Stereotaxis beats ViewRay on 9 of the 14 factors compared between the two stocks.


Stereotaxis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$31.51-3.8%$1.05 billion$27.37 million-43.16Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$26.98-4.0%$913.92 million$495.52 million-49.05
AxoGen logo
AXGN
AxoGen
1.7$18.28-2.6%$745.31 million$106.71 million-29.02News Coverage
SMLR
Semler Scientific
1.2$106.88-2.9%$717.88 million$32.77 million75.26Insider Selling
News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$25.04-3.9%$685.35 million$23.60 million-17.89Increase in Short Interest
ViewRay logo
VRAY
ViewRay
1.5$3.94-5.8%$633.56 million$87.78 million-4.43News Coverage
Zynex logo
ZYXI
Zynex
1.8$14.82-4.7%$516.55 million$45.47 million44.91
Cutera logo
CUTR
Cutera
1.5$27.50-5.5%$489.03 million$181.71 million-15.19Analyst Downgrade
News Coverage
Edap Tms logo
EDAP
Edap Tms
1.3$8.33-2.2%$242.94 million$50.23 million-138.83Increase in Short Interest
Gap Down
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.34-4.9%$204.85 million$3.38 million-3.84Decrease in Short Interest
FONR
FONAR
1.1$17.62-1.6%$115.48 million$85.69 million16.62
IRIDEX logo
IRIX
IRIDEX
0.9$7.07-5.0%$109.73 million$43.45 million-12.85
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.43-3.8%$109.04 millionN/A0.00
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.20-4.1%$91.52 million$10,000.00-1.20
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.10-7.3%$87.70 millionN/A-1.45Analyst Downgrade
Increase in Short Interest
Electromed logo
ELMD
Electromed
1.8$10.10-0.7%$87.21 million$32.47 million24.05
electroCore logo
ECOR
electroCore
1.4$1.74-6.3%$84.35 million$2.39 million-2.20Gap Down
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$17.10-1.2%$39.52 million$1.50 million-0.98
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10-90.1%$38.87 million$40,000.000.00Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.03-5.4%$30.37 million$5.51 million-0.10News Coverage
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
0.6$3.95-13.9%$27.75 million$15.09 million0.00Gap Up
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63-2.7%$27.20 million$6.57 million-0.01
PEYE
Precision Optics
0.4$1.70-0.0%$22.55 million$9.92 million-17.00
Vaso logo
VASO
Vaso
0.9$0.09-0.0%$16.46 million$75.75 million4.44News Coverage
Gap Down
Star Equity logo
STRR
Star Equity
0.1$2.76-3.6%$13.59 million$114.18 million-0.88
Micron Solutions logo
MICR
Micron Solutions
0.3$3.13-13.4%$10.33 million$17.50 million22.32
GTHP
Guided Therapeutics
0.3$0.72-11.1%$9.49 million$40,000.00-3.00
NIMU
Non-Invasive Monitoring Systems
0.5$0.03-0.0%$2.49 millionN/A0.00Upcoming Earnings
RSLSD
ReShape Lifesciences
0.4N/AN/A$1.94 million$610,000.000.00High Trading Volume
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55-0.0%$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05-0.0%$764,000.00N/A0.00
MAGAA
Magna-Lab
0.7$0.43-188.3%$507,000.00N/A2.39Gap Up
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.02-0.0%$234,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00-0.0%$177,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.00-312.5%$166,000.00N/A0.00News Coverage
Gap Up
ULGX
Urologix
0.6$0.01-0.0%$153,000.00N/A0.00Gap Down
AKSY
Aksys
0.0$0.05-0.0%$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.40-2.5%$0.00$9.40 million-6.67
HRTT
Heart Tronics
0.0$0.02-0.0%$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00-0.0%$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00-94.1%$0.00N/A0.00Gap Up
PECN
Photoelectron
0.2$0.00-0.0%$0.00N/A0.00
Trimedyne logo
TMED
Trimedyne
0.4$4.25-0.2%$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00-0.0%$0.00N/A0.00
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.